

# Jay Lucidarme

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/264522/publications.pdf>

Version: 2024-02-01

41  
papers

1,837  
citations

361413

20  
h-index

276875

41  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1157  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Review of Vaccines, 2022, 21, 739-751.	4.4	7
2	Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review. Journal of Infection, 2022, 84, 289-296.	3.3	26
3	Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. The Lancet Child and Adolescent Health, 2022, 6, 96-105.	5.6	18
4	Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England. Vaccine, 2022, 40, 1493-1498.	3.8	3
5	First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England. Clinical Infectious Diseases, 2021, 73, e1661-e1668.	5.8	45
6	4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents. Infectious Diseases and Therapy, 2021, 10, 307-316.	4.0	17
7	UK guidelines and testing for invasive meningococcal disease. Lancet Infectious Diseases, The, 2021, 21, 455-456.	9.1	3
8	Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England. Vaccine, 2021, 39, 2719-2729.	3.8	8
9	Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLoS ONE, 2021, 16, e0260677.	2.5	19
10	Invasive serogroup B meningococci in England following three years of 4CMenB vaccination – first real-world data. Journal of Infection, 2021, , .	3.3	4
11	Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates. Journal of Infection, 2020, 80, 54-60.	3.3	5
12	Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England. Journal of Infection, 2020, 80, 182-189.	3.3	11
13	Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative. Journal of Infection, 2020, 81, 698-711.	3.3	51
14	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine, 2020, 38, 7542-7550.	3.8	25
15	Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. Journal of Infection, 2020, 81, 575-584.	3.3	9
16	Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet, The, 2020, 395, 1865-1877.	13.7	32
17	The global meningitis genome partnership. Journal of Infection, 2020, 81, 510-520.	3.3	13
18	Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. New England Journal of Medicine, 2020, 382, 309-317.	27.0	154

#	ARTICLE	IF	CITATIONS
19	Genomic analysis of the meningococcal ST-4821 complexâ€“Western clade, potential sexual transmission and predicted antibiotic susceptibility and vaccine coverage. <i>PLoS ONE</i> , 2020, 15, e0243426.	2.5	7
20	Detection of the United States <i>Neisseria meningitidis</i> urethritis clade in the United Kingdom, August and December 2019 â€“ emergence of multiple antibiotic resistance calls for vigilance. <i>Eurosurveillance</i> , 2020, 25, .	7.0	16
21	Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe. <i>Journal of Infection</i> , 2019, 79, 528-541.	3.3	29
22	Invasive meningococcal disease in patients with complement deficiencies: a case series (2008â€“2017). <i>BMC Infectious Diseases</i> , 2019, 19, 522.	2.9	34
23	Potential of Phase Variation in Multiple Outer-Membrane Proteins During Spread of the Hyperinvasive <i>Neisseria meningitidis</i> Serogroup W ST-11 Lineage. <i>Journal of Infectious Diseases</i> , 2019, 220, 1109-1117.	4.0	8
24	Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays. <i>Methods in Molecular Biology</i> , 2019, 1969, 169-179.	0.9	10
25	The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. <i>Expert Review of Vaccines</i> , 2019, 18, 15-30.	4.4	136
26	Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. <i>Eurosurveillance</i> , 2019, 24, .	7.0	20
27	Targeted DNA enrichment and whole genome sequencing of <i>Neisseria meningitidis</i> directly from clinical specimens. <i>International Journal of Medical Microbiology</i> , 2018, 308, 256-262.	3.6	36
28	Phase Variation of <i>NadA</i> in Invasive <i>Neisseria meningitidis</i> Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	14
29	Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing <i>Neisseria meningitidis</i> strain coverage by meningococcal vaccines. <i>PLoS ONE</i> , 2018, 13, e0197186.	2.5	14
30	Frequent capsule switching in â€“ultra-virulentâ€™ meningococci â€“ Are we ready for a serogroup B ST-11 complex outbreak?. <i>Journal of Infection</i> , 2017, 75, 95-103.	3.3	30
31	Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. <i>Pediatrics</i> , 2017, 140, .	2.1	38
32	Molecular characterization of invasive capsule null <i>Neisseria meningitidis</i> in South Africa. <i>BMC Microbiology</i> , 2017, 17, 40.	3.3	17
33	Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e473-e482.	10.0	73
34	Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. <i>Journal of Infection</i> , 2016, 73, 63-70.	3.3	7
35	An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. <i>Eurosurveillance</i> , 2016, 21, .	7.0	98
36	Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1420-1428.	9.1	63

#	ARTICLE	IF	CITATIONS
37	Increase in Endemic <i>Neisseria meningitidis</i> Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales. <i>Clinical Infectious Diseases</i> , 2015, 60, 578-585.	5.8	191
38	Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. <i>Journal of Infection</i> , 2015, 71, 544-552.	3.3	185
39	Genotypic Analysis of Meningococcal Factor H-Binding Protein from Non-Culture Clinical Specimens. <i>PLoS ONE</i> , 2014, 9, e89921.	2.5	16
40	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 416-425.	9.1	261
41	Characterization of <i>Neisseria meningitidis</i> Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein. <i>Vaccine Journal</i> , 2011, 18, 1002-1014.	3.1	84